Antitumor effects of non-replicative herpes simplex vectors expressing antiangiogenic proteins and thymidine kinase on Lewis lung carcinoma establishment and growth

Cancer Gene Therapy

Volumn 14, Issue 9, 2007, Pages 791-801

  Berto, E ^a   Bozac, A ^a   Volpi, I ^a   Lanzoni, I ^a   Vasquez, F ^a   Melara, N ^a   Manservigi, R ^a   Marconi, P ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Angiogenesis inhibitors; Combined anticancer treatment; HSV 1 non replicative vector; Suicide gene

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ENDOSTATIN; GANCICLOVIR; THYMIDINE KINASE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; ENDOTHELIUM CELL; FEMALE; HERPES SIMPLEX VIRUS; IN VITRO STUDY; IN VIVO STUDY; LEWIS CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CARCINOMA, LEWIS LUNG; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; DEFECTIVE VIRUSES; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; HUMANS; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; THYMIDINE KINASE; VERO CELLS; VIRUS REPLICATION;

HERPES; HUMAN HERPESVIRUS 1; MUS;

EID: 34547880028     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7701058     Document Type: Article

References (36)

1. Folkman J, Haudenschild C. Angiogenesis in vitro. Nature 1980; 288: 551-556.
2. Kim YM, Hwang S, Pyun BJ, Kim TY, Lee ST, Gho YS et al. Endostatin blocks vascular endothelial growth factormediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 2002; 277: 27872-27879.
3. Claesson-Welsh L, Welsh M, Ito N, Anand-Apte B, Soker S, Zetter B et al. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc Natl Acad Sci USA 1998; 95: 5579-5583.
4. Parsons-Wingerter P, Lwai B, Yang MC, Elliott KE, Milaninia A, Redlitz A et al. A novel assayof angiogenesis in the quail chorioallantoic membrane: stimulation by bFGF and inhibition by angiostatin according to fractal dimension and grid intersection. Microvasc Res 1998; 55: 201-214.
5. Ji WR, Barrientos LG, Llinas M, Gray H, Villarreal X, DeFord ME et al. Selective inhibition by kringle 5 of human plasminogen on endothelial cell migration, an important process in angiogenesis. Biochem Biophys Res Commun 1998; 247: 414-419.
6. Cao Y, Chen A, An SS, Ji RW, Davidson D, Llinas M. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem 1997; 272: 22924-22928.
7. Beerepoot LV, Witteveen EO, Groenewegen G, Fogler WE, Sim BK, Sidor C et al. Recombinant human angiostatin by twice-dailysubcutaneous injection in advanced cancer: a pharmacokinetic and long-term safetystudy. Clin Cancer Res 2003; 9: 4025-4033.
8. Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C et al. Phase I studyof recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2002; 20: 3792-3803.
9. Twombly R. First clinical trials of endostatin yield lukewarm results. J Natl Cancer Inst 2002; 94: 1520-1521.
10. Thomas JP, Arzoomanian RZ, Alberti D, Marnocha R, Lee F, Friedl A et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2003; 21: 223-231.
11. Kerbel RS, Klement G, Pritchard KI, Kamen B. Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratoryinto the oncologyclinic. Ann Oncol 2002; 13: 12-15.
12. Berto E, Bozac A, Marconi P. Development and application of replication-incompetent HSV-1-based vectors. Gene Therapy 2005; 12(Suppl 1): S98-S102.
13. Krisky DM, Marconi PC, Oligino TJ, Rouse RJ, Fink DJ, Cohen JB et al. Development of herpes simplex virus replication-defective multigene vectors for combination gene therapyapplications. Gene Therapy 1998; 5: 1517-1530.
14. Marconi P, Tamura M, Moriuchi S, Krisky DM, Niranjan A, Goins WF et al. Connexin 43-enhanced suicide gene therapyusing herpesviral vectors. Mol Ther 2000; 1: 71-81.
15. Niranjan A, Moriuchi S, Lunsford LD, Kondziolka D, Flickinger JC, Fellows W et al. Effective treatment of experimental glioblastoma by HSV vector-mediated TNF alpha and HSV-tk gene transfer in combination with radiosurgeryand ganciclovir administration. Mol Ther 2000; 2: 114-120.
16. Raffaella R, Gioia D, De Andrea M, Cappello P, Giovarelli M, Marconi P et al. The interferon-inducible IFI16 gene inhibits tube morphogenesis and proliferation of primary, but not HPV16 E6/E7-immortalized human endothelial cells. Exp Cell Res 2004; 293: 331-345.
17. Chen SH, Chen XH, Wang Y, Kosai K, Finegold MJ, Rich SS et al. Combination gene therapyfor liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci USA 1995; 92: 2577-2581.
18. Vile RG, Castleden S, Marshall J, Camplejohn R, Upton C, Chong H. Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int J Cancer 1997; 71: 267-274.
19. Smythe WR, Hwang HC, Amin KM, Eck SL, Davidson BL, Wilson JM et al. Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization system. Cancer Res 1994; 54: 2055-2059.
20. Ram Z, Culver KW, Oshiro EM, Viola JJ, DeVroom HL, Otto E et al. Therapyof malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 1997; 3: 1354-1361.
21. Shalev M, Kadmon D, Teh BS, Butler EB, Aguilar-Cordova E, Thompson TC et al. Suicide gene therapytoxicity after multiple and repeat injections in patients with localized prostate cancer. J Urol 2000; 163: 1747-1750.
22. Sandmair AM, Loimas S, Puranen P, Immonen A, Kossila M, Puranen M et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 2000; 11: 2197-2205.
23. Moolten FL. Drug sensitivity('suicide') genes for selective cancer chemotherapy. Cancer Gene Ther 1994; 1: 279-287.
24. Krisky DM, Marconi PC, Oligino T, Rouse RJ, Fink DJ, Glorioso JC. Rapid method for construction of recombinant HSV gene transfer vectors. Gene Therapy 1997; 4: 1120-1125.
25. Marconi P, Krisky D, Oligino T, Poliani PL, Ramakrishnan R, Goins WF et al. Replication-defective herpes simplex virus vectors for gene transfer in vivo. Proc Natl Acad Sci USA 1996; 93: 11319-11320.
26. Mosmann T. Rapid colorimetric assayfor cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
27. Sasaki T, Fukai N, Mann K, Gohring W, Olsen BR, Timpl R. Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin. EMBO J 1998; 17: 4249-4256.
28. Dhanabal M, Ramchandran R, Volk R, Stillman IE, Lombardo M, Iruela-Arispe ML et al. Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res 1999; 59: 189-197.
29. Griscelli F, Li H, Bennaceur-Griscelli A, Opolon P, Soria C, Perricaudet M et al. Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci USA 1998; 95: 6367-6372.
30. Kuo CJ, Farnebo F, Yu EY, Christofferson R, Swearingen RA, Carter R et al. Comparative evaluation of the antitumor activityof antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci USA 2001; 98: 4605-4610.
31. van der Schaft DW, Seftor RE, Seftor EA, Hess AR, Gruman LM, Kirschmann DA et al. Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst 2004; 96: 1473-1477.
32. Young MR. Tumor skewing of CD34+progenitor cell differentiation into endothelial cells. Int J Cancer 2004; 109: 516-524.
33. Teicher BA, Holden SA, Ara G, Sotomayor EA, Huang ZD, Chen YN et al. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer 1994; 57: 920-925.
34. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7: 987-989.
35. Li H, Lindenmeyer F, Grenet C, Opolon P, Menashi S, Soria C et al. AdTIMP-2 inhibits tumor growth, angiogenesis, and metastasis, and prolongs survival in mice. Hum Gene Ther 2001; 12: 515-526.
36. Vile RG, Diaz RM, Castleden S, Chong H. Targeted gene therapyfor cancer: herpes simplex virus thymidine kinase gene-mediated cell killing leads to anti-tumour immunity that can be augmented by co-expression of cytokines in the tumour cells. Biochem Soc Trans 1997; 25: 717-722.